Clinical trial · Interventional
Surgery With Extended (D3) Mesenterectomy for Small Bowel Tumors
NCT05670574CI-TRIAL-00063009unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study is designed to investigate the safety and efficacy of central D3 lymphadenectomy in cases of small bowel tumors. Such dissection is under debate; consensus guidelines are vague when it comes to surgical techniques and practice is highly variable.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymph Node Metastases | — | UNRESOLVED | — |
| Quality of Life | — | UNRESOLVED | — |
| Small Bowel Cancer | Small Intestinal Carcinoma | ALIAS | 0.90 |
| Small Bowel Carcinoid Tumor | — | UNRESOLVED | — |
| Tumor Metastasis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Surgery with extended (D3) mesenterectomy for small bowel tumors | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Number of lymph nodes in total in D2 and D3 areas
- timeFrame
- 1 month
- measure
- Number of positive lymph nodes in D2 and D3 areas
- timeFrame
- 1 month
Secondary outcomes (10)
- measure
- Complications
- timeFrame
- 30 days
- measure
- Peroperative blood loss
- timeFrame
- 30 days
- measure
- Hospitalization time
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients included must be able to fill in an informed, written consent and to understand its implications and contents and to participate in the follow-up * Radiologically/scintigraphically/histologically verified extraduodenal tumor(-s) in the small bowel and/or in the mesentery of the small bowel * No signs of inoperability * Fit for general anesthetics Exclusion Criteria: * Extraduodenal small bowel tumors verified as GIST or benign tumor * Widespread lymphoma
References
Publications (2)
- DERIVEDVasic T, Stimec M, Stimec BV, Edwin B, Ignjatovic D. Lymphatic and vascular anatomy define surgical principles for radical treatment of distal duodenal and proximal jejunal tumors. Surg Endosc. 2025 Aug;39(8):5421-5429. doi: 10.1007/s00464-025-11909-9. Epub 2025 Jul 7. PMID 40624418
- DERIVEDVasic T, Stimec MB, Stimec BV, Kjaestad E, Ignjatovic D. Jejunal Lymphatic and Vascular Anatomy Defines Surgical Principles for Treatment of Jejunal Tumors. Dis Colon Rectum. 2025 May 1;68(5):553-561. doi: 10.1097/DCR.0000000000003644. Epub 2025 Feb 12. PMID 39936801